Get the BLPH Research Report and
Also Receive Our Top Trades for 2016!

Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016. “I am pleased with the progress in our ongoing clinical programs to treat pulmonary hypertension in unmet or under-served chronic pulmonary disease areas,” stated Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. “Importantly, we are delighted by the FDA’s recent agreement with … (See Research Report)
Download Research Report
on BLPH Now